WO2021062033A1
|
|
Fusion polypeptides binding antibody fc domains and integrin and methods of use
|
WO2021050936A1
|
|
Methods of treatment with cd8 t cell-mediated immune therapy
|
US2019175709A1
|
|
Genetic expression of hla molecules to enhance immunotherapies
|
WO2019032560A1
|
|
Intestinal lengthening device
|
KR20200015717A
|
|
Utilization of CD39 and CD103 for Identification of Human Tumor Reactive T Cells for Cancer Treatment
|
EP3268387A1
|
|
Compositions and methods for enhancing the efficacy of cancer therapy
|
US2017216420A1
|
|
Bacterial vaccines deficient in the 2-C-methyl-D-erythritol-4-phosphate pathway and methods of preparation and use thereof
|
AU2013263717A1
|
|
Trimeric OX40L-immunoglobulin fusion protein and methods of use
|
WO2013130102A2
|
|
Dual ox40 agonist/il-2 cancer therapy methods
|
EP2812022A1
|
|
Method of monitoring cancer treatment using ox40 agonists
|
AU2011265482A1
|
|
Trimeric OX40L-immunoglobulin fusion protein and methods of use
|
TW201309328A
|
|
Alumina nanoparticle bioconjugates and methods of stimulating an immune response using said bioconjugates
|
EP2608811A1
|
|
Alumina nanoparticle bioconjugates and methods of stimulating an immune response using said bioconjugates
|